



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07H 1/02, 21/00, 21/04</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/04036 (43) International Publication Date: 27 January 2000 (27.01.00)</p>
<p>(21) International Application Number: PCT/US99/15997 (22) International Filing Date: 15 July 1999 (15.07.99) (30) Priority Data: 60/092,963 15 July 1998 (15.07.98) US (71) Applicant: DUKE UNIVERSITY [US/US]; 230 North Building, Research Drive, P.O. Box 90083, Durham, NC 27708-0083 (US). (72) Inventors: PIRRUNG, Michael, C.; B120 Levine Science Research Center, Duke University, Durham, NC 27708-0083 (US). ZHAO, Xiaodong; B120 Levine Science Research Center, Duke University, Durham, NC 27708-0083 (US). (74) Agent: WILSON, Mary, J.; Nixon & Vanderhye, P.C., Suite 800, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).</p>		<p>(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>
<p>(54) Title: PHOTOCLEAVABLE NUCLEOSIDE BASE (57) Abstract The present invention relates, in general, to a nucleoside base and, in particular, to a universal, photocleavable nucleoside base. The invention further relates to oligonucleotides comprising such a base.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PHOTOCLEAVABLE NUCLEOSIDE BASE

This application claims priority from Provisional Application No. 60/092,963, filed July 15, 1998, the disclosure of which is incorporated herein by

5 reference.

This invention was made with U.S. Government support under Grant No. 95-08-0023 awarded by the National Institute of Standards and Technology, Advanced Technology Program. The U.S. Government has
10 certain rights in the invention.

TECHNICAL FIELD

The present invention relates, in general, to a nucleoside base and, in particular, to a universal, photocleavable nucleoside base. The invention further
15 relates to oligonucleotides comprising such a base.

BACKGROUND

A variety of novel techniques for analysis of nucleic acids best utilize relatively short, single-stranded analytes. Many such techniques are based on
20 the hybridization of analyte nucleic acids to miniaturized arrays of short (<25 nucleotides), single-stranded DNA probes (Ramsay, Nat. Biotechnol. 16:40 (1998); Marshall et al, J. Nat. Biotechnol. 16:27 (1998)). Samples of analyte DNA often arise by PCR
25 amplification from a biological sample, range from hundreds to thousands of nucleotides and are obtained as double-stranded molecules. As hybridization

requires single-stranded nucleic acids, various means have been devised to render amplification products single-stranded.

5 The stability of duplex nucleic acid is directly proportional to molecular length. Thus, it can be difficult to form single-stranded analytes from long, double-stranded amplicons. Further, it has been observed in some instances that the performance of various nucleic acid analysis techniques, such as the
10 above-referenced array-based methods, is superior with shorter analyte nucleic acids. This has created a demand for methods of fragmenting analyte nucleic acid or amplification products thereof.

15 Available fragmentation methods include limited restriction digestion of the amplicon, as well as the incorporation of uridine during amplification followed by backbone cleavage using uracil-N-glycosylase. These methods, however, have drawbacks related to their sequence bias and the additional processing steps
20 needed to remove reagents/byproducts. Accordingly, there is a clear need for a nucleoside analog that can be enzymatically incorporated at random within a nucleic acid chain and subsequently activated for cleavage of the backbone.

25 A number of workers have developed analogs of the heterocyclic bases in nucleic acids for various purposes. For example, Bergstrom et al have advanced nitropyrrole and nitroindole as heterocycles that are accepted opposite any of the natural bases in double-
30 stranded nucleic acid (Bergstrom et al, Nucleic Acids

Res. 25:1935 (1997); Bergstrom et al, J. Am. Chem. Soc. 117:1201 (1995)). Such "universal" bases have uses including simplified syntheses of short oligonucleotides that are suitable for use as probes
5 for hybridization, and as primers for DNA sequencing and nucleic acid amplification. On the other hand, Kool et al have shown that difluorotoluene specifically substitutes for the base thymidine (T) in duplex DNA with only a small loss in hybrid stability (Schweitzer
10 et al, J. Org. Chem. 59:7238 (1994)). Further, difluorotoluene is accepted by DNA polymerases either in the template strand or as an incoming triphosphate (Moran et al, Proc. Natl. Acad. Sci. USA 94:10506 (1997); Moran et al, J. Am. Chem. Soc. 119:2056 (1997);
15 Liu et al, Chem. Biol. 4:919 (1997)). As a result, high fidelity complementation of the unnatural base with a natural adenine (A) occurs. Finally, Ordoukhanian et al (J. Am. Chem. Soc. 117:9570 (1995)) have developed unnatural base analogs that can be
20 cleaved into two portions (and thereby cleave the backbone of the nucleic acid) by irradiation. These compounds do not resemble natural nucleosides and are not accepted by nucleic acid modifying enzymes. Thus, they must be incorporated into oligonucleotides by
25 chemical synthesis.

The present invention provides a nucleoside analog that can be enzymatically incorporated into a nucleic acid chain and then activated for cleavage of that chain.

SUMMARY OF THE INVENTION

The present invention relates to a nucleoside base that can be randomly incorporated into newly-synthesized nucleic acid strands by enzymes, and, in a subsequent step, cleaved by UV irradiation, thereby introducing single-strand nicks into double-stranded nucleic acid. Such nicks fragment larger nucleic acids into smaller ones. Because the nicks are random and, therefore, not opposed by nicks on the opposite strand, the average length of uninterrupted double stranded nucleic acid is shortened, facilitating conversion from double-stranded to single-stranded nucleic acid.

Objects and advantages of the invention will be clear from the description that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a P* base-containing nucleoside (derivatized with toluoyl groups) (1), a P* base-containing 5'-dimethoxytrityl-3'-cyanoethyl(diisopropyl) phosphoramidite (2) and a P* base-containing nucleoside triphosphate (3).


Figure 2 shows extension products obtained using primer 7 and template 5.

Figure 3 shows fragments resulting from irradiation of a P* base-containing oligonucleotide.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a photocleavable, universal nucleoside base (designated the "P*" base), and nucleosides and oligonucleotides comprising same.

- 5 Nucleosides of the invention comprise the photocleavable P* base moiety and a sugar moiety and are of the formula



- wherein R_1 and R_2 are, independently, H, OH or OCH_3 , R_3 and R_4 are, independently, H, a protecting group (such as a toluoyl moiety), or a mono-, di- or triphosphate, and X is O or S. The nitro-substituted aromatic ring of the P* base moiety can be further substituted, at any or all available positions on the ring, with, for example, an electron-donating oxygen functionality (e.g., an alcohol or an ether), with a halogen (e.g., F) or with a lower (e.g., $\text{C}_1\text{-C}_4$) alkyl. Most commonly, the sugar moiety of the nucleoside of the invention is D-deoxyribose, as found in naturally occurring deoxyribonucleosides.
- 20
- 25

Methods of preparing P* base-containing nucleosides of the invention can be exemplified by the preparation of (nitropiperonyl)deoxyriboside. In that regard, a deoxyribosyl chloride is treated with an

aromatic Grignard reagent followed by nitration.
Conversion to an H phosphonate or to the
5'-dimethoxytrityl-3'-cyanoethyl(diisopropyl)
phosphoramidite can then be effected, for example, for
5 incorporation into oligonucleotides by conventional
automated synthesis techniques (see, for example,
M.J. Gait, Oligonucleotide Synthesis, IRC Press,
Washington, D.C. (1984)). Conversion to the
triphosphate can be effected in accordance with the
10 method of Ludwig et al (Org. Chem. 54:631 (1989)) and
the resulting triphosphate then enzymatically
incorporated into nucleic acids using, for example, *E.*
coli DNA polymerase I or Klenow DNA polymerase. The
frequency of incorporation of the P* base can be varied
15 by altering the concentration of P* base-containing
nucleoside in the reaction mixture.

The effect on hybrid formation when P* base
opposes the four native bases is be small (e.g., <5°C
in melting temperature). Further, P* base is able to
20 promote incorporation of three native dNTPs (A, G, and
T) when in the template strand of a primer-template
complex.

Duplexes containing the P* base can be cleaved by
irradiation. Preferably, long wavelength UV
25 irradiation is used (e.g., >350 nm) for a relatively
brief period (e.g., about 30 min), followed by base
treatment (e.g., with piperidine or K₂CO₃, for example,
at room temperature, at about 37°C or at about 95°C).

The nucleosides of the invention have application
30 in a variety of settings. For example, P* base-

containing nucleosides are particularly suitable for use in the production of oligonucleotides ultimately requiring fragmentation prior to utilization. Since P* base can be randomly incorporated into newly-synthesized nucleic acids and subsequently activated for cleavage by UV irradiation, it can be used to shorten the average length of uninterrupted double-stranded nucleic acid, thereby facilitating conversion to single-stranded nucleic acids. As indicated above single-stranded nucleic acids can be used in analyses based on hybridization of analyte nucleic acids to single stranded DNA probes, present, for example, in miniaturized arrays.

Certain aspects of the present invention are described in greater detail in the non-limiting Examples that follow.

EXAMPLES

The following experimental details are relevant to the Examples that follow.

Materials and Methods.

^1H and ^{31}P NMR spectra were recorded on GE QE-300 and Varian Inova-400 spectrometers. NOESY were recorded on a Varian Unity 500 MHz spectrometer. Mass spectra were measured on a JEOL-JMS-SX-102 with a FAB/MS source. Infrared spectra were recorded on a BOMEM MB-100 FT-IR spectrometer. Ultraviolet spectra were measured on a

Shimadzu UV160U UV-visible spectrophotometer. The melting curves were recorded on an Aviv 62DS spectrophotometer. Melting points were measured on a HAAKE BUCHLER Melting Point Apparatus. Photolysis was performed in a Rayonet Photochemical Reactor. X-ray data were collected on a Siemens SMART diffractometer. High pressure liquid chromatography (HPLC) was carried out on a Hewlett Packard series 1100 with an Alltech C-18 reverse phase column (10 mm x 250 mm). T4 polynucleotide kinase and Klenow fragment DNA polymerase were purchased from New England Biolabs. All the reactions were performed under argon atmosphere and freshly distilled anhydrous solvent when it is necessary.

15

Synthesis

2'-deoxy-1'-piperonyl-3',5'-di-O-toluoyl-D-ribofuranose. To 5 mL of dry tetrahydrofuran (THF) and magnesium turnings (120 mg, 5mmol) was added 4-bromo-1,2-methylenedioxybenzene (1.03 g, 5 mmol). The reaction was initiated by adding a few I₂ crystals and kept at ~40°C for 1 hr. CdCl₂ powder (450 mg, 2.5 mmol) was added. After refluxing for 1.5 hr, the mixture was cooled to room temperature. 1'-α-Chloro-3',5'-di-O-toluoyl-2'-deoxyribose (1.50g, 3.8 mmol), prepared as reported by Hoffer, was added and stirred over 6 hr. The reaction was quenched with aqueous NH₄Cl and extracted with ethyl acetate. The extract was washed with saturated NaHCO₃ solution, saturated NaCl solution and dried over anhydrous Na₂SO₄. The

products were purified by flash chromatography on silica gel with 12% ethyl acetate in hexane as the eluant. The products (1.60 g, 3.3 mmol) were obtained as a clear oil (epimer α/β , 10:1) at a yield of 87%.

5

Conversion to 2'-deoxy-1' β -piperonyl-3',5'-di-O-toluoyl-D-ribofuranose. To 75 mL of toluene were added the α/β epimer mixture (1.00g) and a catalytic amount of toluenesulfonic acid (100 mg) and one drop of concentrated sulfuric acid and five drops of water. After refluxing for 2 hr, toluene was removed and the residue was neutralized with a NaHCO₃ aqueous solution, and extracted with ethyl acetate. The extract was washed with saturated NaCl solution and dried over anhydrous Na₂SO₄. The α and β epimers were isolated by flash chromatography on silica gel with 12.5% ethyl acetate in hexane as the eluant. α epimer, 0.30 g (30%), ¹H NMR (300 MHz, CDCl₃, ppm, referenced to TMS at 0.00) δ 7.95 (2H, d, J = 8.2 Hz), 7.78 (2H, d, J = 8.2 Hz), 7.23 (2H, d, J = 8.3 Hz), 7.20 (2H, d, J = 8.3 Hz), 6.97-6.76 (3H, m), 5.94 (2H, s, CH₂), 5.58 (1H, m, H1'), 5.26 (1H, m, H3'), 4.66 (1H, m, H4'), 4.56 (2H, m, H5'5''), 2.89 (1H, m, H2' α), 2.40 (6H, s, 2xCH₃), 2.11 (1H, m, H2' β); IR (CDCl₃ thin film, cm⁻¹), 2922, 2852, 1720, 1271, 1104; β epimer, 0.46 g (46%), ¹H NMR (300 MHz, CDCl₃, ppm, referenced to TMS at 0.00) δ 7.97 (2H, d, J = 8.3 Hz), 7.96 (2H, d, J = 8.3 Hz), 7.27 (2H, d, J = 8.0 Hz), 7.23 (2H, d, J = 8.0 Hz), 6.90-

25

6.74 (3H, m), 5.94 (2H, s, CH₂), 5.58 (1H, dd, J = 1.3, 4.8 Hz, H1'), 5.16 (1H, dd, J = 5.0, 10.9 Hz, H3'), 4.63 (2H, m, H5'5''), 4.50 (1H, m, H4'), 2.49 (1H, m, H2'β), 2.44 (3H, s, CH₃), 2.41 (3H, s, CH₃), 2.22 (1H, m, H2'α); IR (CDCl₃ thin film, cm⁻¹), 2921, 1719, 1611, 1271, 1105; HRMS (FAB) m/z calcd for C₂₈H₂₆O₇ 474.1678, found 474.1682.

2'-deoxy-1'β-nitropiperonyl-3',5'-di-O-toluoyl-D-
10 ribofuranose. To a 175 mL acetic anhydride solution of 2'-deoxy-1'β-piperonyl-3',5'-di-O-toluoyl-D-ribofuranose (1.40 g, 2.95 mmol), immersed in an ice-water bath, was added Cu(NO₃)₂•3H₂O (2.57 g, 9.38 mmol). The resulting solution was stirred for 25 min.
15 The mixture was poured into 200 mL of a NaHCO₃ aqueous solution and extracted with ethyl acetate. The extract was washed with a saturated NaCl solution and dried over anhydrous Na₂SO₄. The product was purified by flash chromatography on silica gel with 18% ethyl
20 acetate in hexane as the eluant. The product (1.38g, 2.65 mmol) was obtained as a yellow oil (epimer α/β, 9:1) at a yield of 90%. ¹H NMR (300 MHz, CDCl₃, ppm, referenced to TMS at 0.00) δ 7.98 (2H, d, J = 8.2Hz, Tol-H), 7.93 (2H, d, J = 8.2 Hz, Tol-H), 7.54 (1H, s, Ar-H), 7.37 (1H, s, Ar-H), 7.27 (2H, d, J = 8.0 Hz, Tol-H), 7.22 (2H, d, J = 8.0 Hz, Tol-H), 6.09 (1H, d, J = 6.6 Hz, CH₂), 6.08 (1H, d, J = 6.6 Hz, CH₂), 5.77 (1H, dd, J = 5.1, 10.2 Hz, H1'), 5.58 (1H, dd, J = 1.8, 4.8 Hz, H3'), 4.72 (2H, m, H5'5''), 4.51 (1H, m, H4'),

2.94 (1H, ddd, $J = 1.2, 5.1, 6.4$ Hz, $H2'\beta$), 2.43 (3H, s, CH_3), 2.40 (3H, s, CH_3), 2.05 (1H, m, $H2'\alpha$); IR ($CDCl_3$ thin film, cm^{-1}), 2922, 2853, 1712, 1611, 1503, 1482, 1268, 1177, 1106; HRMS (FAB) m/z calcd for $C_{28}H_{25}NO_9$ 519.1529, found 519.1539.

2'-deoxy-1' β -nitropiperonyl-D-ribofuranose. To a 30 mL methanol solution of 2'-deoxy-1' β -nitropiperonyl-3',5'-di-O-toluoyl-D-ribofuranose (0.22g, 0.42 mmol), was added 0.5 M sodium methoxide in methanol (7.5 mL) and stirred for 45 min. The reaction was quenched by adding NH_4Cl powder, and then filtered and concentrated and flash chromatographed on silica gel with 8:2 ethyl acetate/hexane. The product was obtained as a yellow solid (0.12 g, 0.42 mmol) at a yield of 100%. UV(H_2O): $\lambda_{max} = 360.5$ nm, ϵ (360.5 nm) = 1.3×10^4 , UV(CH_3OH): $\lambda_{max} = 346.0$ nm, ϵ (346.0 nm) = 1.4×10^4 ; mp 133-134°C; 1H NMR (300 MHz, $CDCl_3$, ppm, referenced to TMS at 0.00) δ 7.54 (1H, s, Ar-H), 7.31 (1H, s, Ar-H), 6.12 (1H, d, $J = 3.0$ Hz, CH_2), 6.11 (1H, d, $J = 3.0$ Hz, CH_2), 5.68 (1H, dd, $J = 6.0, 9.0$ Hz, $H1'$), 4.40 (1H, m, $H3'$), 4.02 (1H, m, $H4'$), 3.93 (2H, m, $H5'5''$), 2.63 (1H, ddd, $J = 3.0, 6.0, 8.9$ Hz, $H2'\beta$), 1.92 (1H, m, $H2'\alpha$); IR ($CDCl_3$ thin film, cm^{-1}), 3396 (br), 2931, 2857, 1520, 1504, 1482, 1329, 1255, 1033; HRMS (FAB) m/z calcd for $C_{12}H_{13}NO_7$ 283.0692, found 283.0686.

2'-deoxy-1' β -nitropiperonyl-5'-O-trityl-D-ribofuranose.

To 10 mL pyridine solution of 2'-deoxy-1' β -nitropiperonyl-D-ribofuranose (0.11 g, 0.39 mmol) and triethyl amine (0.15 mL) and N,N-dimethylaminopyridine
5 (5 mg, 0.041 mmol), was added dimethoxytrityl chloride (0.194 mg, 0.50 mmol). After stirring for 6 hr, the reaction then poured in 50 mL of water and extracted with ethyl acetate. The extract was washed with a saturated NaHCO₃ solution, a saturated NaCl solution
10 and dried over anhydrous Na₂SO₄. The product was obtained as yellow foam (0.16 g, 0.27 mmol) at a yield of 69% after flash chromatography on silica gel with 27.5% ethyl acetate in hexane as the eluant. ¹H NMR (300 MHz, CDCl₃, ppm, referenced to TMS at 0.00) δ
15 7.55-7.19 (11H, m, Ar-H), 6.84 (4H, d, J = 8.8 Hz), 6.09 (2xH, 2xd, J = 8.4 Hz, CH₂), 5.69 (1H, dd, J = 6.2, 8.8 Hz, H1'), 4.38 (1H, m, H3'), 4.06 (1H, m, H4'), 3.79 (6H, s, 2xOCH₃), 3.38 (2H, m, H5'5''), 2.62 (1H, ddd, J = 3.1, 6.1, 9.3 Hz, H2' β), 1.96 (1H, m,
20 H2' α); IR (CDCl₃ thin film, cm⁻¹), 2927, 1511, 1480, 1257, 1034; HRMS (FAB) m/z calcd for C₃₃H₃₁NO₉, 585.1998, found 585.1983.

2'-deoxy-1' β -nitropiperonyl-3'-O-phosphoramidite-5'-O-trityl-D-ribofuranose. 2'-deoxy-1' β -nitropiperonyl-5'-O-trityl-D-ribofuranose (60 mg, 0.103 mmol) was
25 dissolved in 4 mL of CH₂Cl₂ and 1 mL of triethyl amine, to which was added 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (0.10 mL, 0.44 mmol).

After stirring for 3 hr, the solvent was removed under vacuum and the mixture was loaded to a silica gel column and eluted with 30% ethylacetate in hexane. The products were obtained as a light yellowish oil in two isomers (60 mg, 0.076 mmol) at a yield of 76%. ¹H NMR (300 MHz, CDCl₃, ppm, referenced to TMS at 0.00) δ 7.55-7.20 (11H, m, Ar-H), 6.84 (4H, m), 6.10 (2H, m, CH₂), 5.67 (1H, m, H1'), 4.46 (1H, m), 4.21 (1H, m), 3.86 (1H, m), 3.80 (3H, s, OCH₃), 3.79 (3H, s, OCH₃), 3.62 (2H, m), 3.32 (1H, m), 2.78 (1H, m), 2.65 (2H, m, CH₂), 2.43 (2H, m, CH₂), 1.92 (1H, m), 1.17 (12H, d, J = 6.8 Hz, 4x CH₃); ³¹P NMR (400 MHz, CDCl₃, ppm, referenced to TMP at 0.00) δ 149.24, 148.33; IR (CDCl₃ thin film, cm⁻¹), 2958, 2923, 2853, 1605, 1511, 1480, 1462, 1256, 1033; HRMS (FAB) m/z calcd for C₄₂H₄₈N₃O₁₀P 785.3077, found 785.3020.

2'-deoxy'1'β-nitropiperonyl-3'-O-toluoyl-D-ribofuranose. To 7 mL pyridine solution of 2'-deoxy-1'β-nitropiperonyl-D-ribofuranose (0.15 g, 0.53 mmol) and triethyl amine (0.20 mL) and N,N-dimethylaminopyridine (6 mg, 0.049 mmol), was added dimethoxytrityl chloride (0.30 mg, 0.89 mmol). After stirring for 2 hr, extra dimethoxytrityl chloride (0.14 mg, 0.41 mmol) was added and the solution stirred for an additional 4 hr until the completion of tritylation. Toluoyl chloride (0.11g, 0.72 mmol) was added to the reaction and stirred for another 6 hr. The mixture was poured into 20 mL of water and extracted with CH₂Cl₂.

The extract was washed with a saturated NaHCO_3 solution, a saturated NaCl solution and dried over anhydrous Na_2SO_4 . After the solvent was removed, the residue was dissolved in 50 mL of 80% aqueous acetic acid and stirred overnight. After acetic acid was removed under vacuum, the residue was dissolved in 50 mL of water, and extracted with CH_2Cl_2 . The extract was washed with a saturated NaHCO_3 solution, a saturated NaCl solution and dried over anhydrous Na_2SO_4 . The product was obtained as a white-yellowish liquid (0.18 g, 0.46 mmol) at a total yield of 87% after flash chromatography on silica gel with 5% methanol in CH_2Cl_2 as the eluant. ^1H NMR (300 MHz, CDCl_3 , ppm, referenced to TMS at 0.00) δ 7.97 (2H, d, J = 8.2 Hz, Tol-H), 7.54 (1H, s, Ar-H), 7.40 (1H, s, Ar-H), 7.27 (2H, d, J = 7.9 Hz, Ar-H), 6.84 (4H, d, J = 8.8 Hz), 6.12 (1H, d, J = 2.7 Hz, CH_2), 6.11 (1H, d, J = 2.7 Hz, CH_2), 5.71 (1H, dd, J = 5.2, 10.0 Hz, $\text{H1}'$), 5.44 (1H, m, $\text{H3}'$), 4.22 (1H, dd, J = 4.2, 7.3 Hz, $\text{H4}'$), 3.98 (2H, m, $\text{H5}'$), 2.89 (1H, ddd, J = 1.8, 5.3, 7.0 Hz, $\text{H2}'\beta$), 2.43 (3H, CH_3), 2.04 (1H, ddd, J = 6.8, 10.0, 13.8 Hz, $\text{H2}'\alpha$); IR (CDCl_3 thin film, cm^{-1}), 2920, 2848, 1270, 1176, 1033; HRMS (FAB) m/z calcd for $\text{C}_{20}\text{H}_{19}\text{NO}_8$ 401.1110, found 401.1125.

25

2'-deoxy-1' β -nitropiperonyl-D-ribofuranose-5'-O-triphosphate. 2'-deoxy-1' β -nitropiperonyl-3'-O-toluoyl-D-ribofuranose (60 mg, 0.15 mmol) dried over P_2O_5 under vacuum in a desicator overnight was

- dissolved in 100 mL of pyridine and 750 mL of N,N-dimethyl formamide (DMF), to which was added freshly prepared 1 M 2-chloro-4H-1,3,2-benzodioxaphosphin-4-one 0.25 mL and stirred for 20 min. 0.5 M Bis(tri-n-butylammonium) pyrophosphate in DMF (0.75 mL) followed by 0.13 mL of tri-n-butylamine were added and the mixture stirred for 20 min. To the mixture, was added 2 mL of 1% I₂ in pyridine/H₂O (98:2). After stirring for 15 min, excess I₂ was quenched by adding a few drops of NaHSO₃ solution. The mixture was vacuumed to dryness, then dissolved in 10 mL of methanol and 30 mL of concentrated ammonium hydroxide and kept at room temperature for 42 hr. After the solvent was removed, the aqueous portion was extracted with CH₂Cl₂. The aqueous layer was concentrated and purified by anion exchange chromatography with QA52 quaternary ammonium cellulose resin (Whatman). The column was eluted with 1400 mL of a NH₄HCO₃ solution (pH 9.4) in a linear gradient from 0.005-0.2 M. The collected fraction was concentrated by lyophilization and further purified on an HPLC reverse phase C-18 column with a linear gradient of 50 mM triethylammonium acetate (TEAA) in 0-25% acetonitrile.
- 25 Oligonucleotide synthesis. Oligonucleotides were synthesized on an Applied Biosystems 392 DNA/RNA synthesizer with standard phosphoramidite chemistry. An additional 10 min was given to the coupling step for incorporating modified nucleoside. The oligomers were

purified by either HPLC or 12% polyacrylamide gel electrophoresis.

- Melting temperature. Double stranded oligonucleotide
- 5 25-mers at concentration range of 1-20 μM , were dissolved in buffers of 100 mM NaCl, 10 mM sodium phosphate, pH 7.0. Quartz cuvetts with optical path-length of 1cm and 1mm were used to measure the absorbance of the oligonucleotides in the range of 0.4-
- 10 1.2 at 260 nm. An Aviv 62DS spectrophotometer was equipped with a heating program. The samples were heated from 40° to 75°C at an increment of 0.5°C per data point. Each data point was equilibrated for 30 sec with a maximum fluctuation of 0.1°C. The melting
- 15 temperatures (T_m) were determined by taking the first derivatives of the melting curves (absorbance vs temperature). Thermodynamic data were calculated from a two state model.
- 20 Primer extension study. The oligonucleotides were labelled by phosphorylation of the 5' terminal (4 pmol) with T4 polynucleotide kinase (10 unit) and [γ - ^{32}P]ATP (7000 Ci/mmol, 166 μCi , 23 pmol) in 10 μL of 70 mM Tris-HCl, 10 mM MgCl_2 , and 5 mM dithiothreitol (DTT), pH
- 25 7.6. The mixture was incubated at 37°C for 2 hr and purified on a 8% denaturing polyacrylamide gel. Template (25-mer) and primer (11-mer) were annealed by heating to 65°C and slowly cooling to room temperature. The complex (0.1 pmol) was mixed in 10 μL of DNA

polymerase buffer (10 mM Tris-HCl, 5 mM MgCl₂, and 7.5 mM DTT, pH 7.5) with 100 μM individual deoxynucleoside triphosphate (dNTP). The primer extension was initiated by adding Klenow fragment of *E. coli* DNA polymerase I (1 unit) and incubated at 37°C for 2 min and then quenched by adding 1 μL of 25 mM EDTA. The products were lyophilized and resuspended in 10 μL of formamide/dye and resolved on a 12% denaturing polyacrylamide gel. Electrophoresis was run under constant current of 25 mA after 30 min pre-running. The products on autoradiograph were quantified on a computing densitometer (Molecular Dynamics).

Photolysis. 5'-labelled oligonucleotide 25-mer (0.1 pmol) in 10 μL of 1xTE buffer (10 mM Tris-HCl, 1mM EDTA, pH 7.5) was irradiated at 350 nm in a Rayonet Photochemical Reactor. A Pyrex filter was used to cut off the light (<300 nm). A fan was used to keep photolysis close to room temperature. After photolysis at a fluence rate of 400 μW/cm² for 20 min, 90 μL of 1 M piperidine was added and heated to 90°C for 30 min. The solvent was removed and the products were resuspended in 10 μL of formamide/dye and resolved on a 12% denaturing polyacrylamide gel.

EXAMPLE 1

Synthesis of (Nitropiperonyl)deoxyriboside

A P* base-containing nucleoside can be prepared by treatment of ditoluoylribosyl chloride (Hoffer, Chem. Ber. 93:2777 (1960)) with benzodioxol-4-yl Grignard giving a mixture of anomers in a 1:10 α : β ratio (87% yield). The mixture can be rectified by chromatography, giving the β anomer (76%), and the α anomer can be equilibrated with p-TsOH in toluene, giving a 1.5:1 mixture. Cu(NO₃)₂/Ac₂O nitration (90% yield) yields 1 of Fig. 1.

Using conventional methods (see M.J. Gait, Oligonucleotide Synthesis, IRC Press, Washington, D.C. (1984)), 1 of Fig. 1 can be converted to a 5'-dimethoxytrityl-3'-cyanoethyl(diisopropyl)phosphoramidite (2 of Fig. 1) and used in automated DNA synthesis. The phosphoramidite can be used to prepare the pentacosanucleotide 5 (see Table 1).

The hybridization properties of 5 can be compared against sequence 6 (see Table 1) and its single-base variants compared to the parent sequence 4 (see Table 1). Using known methods (Marky et al, Biopolymers 26:1601-1620 (1987)), the thermodynamics of melting can be determined with several different base pairs in the boxed region (see the results summarized in Table 1). These data indicate that P* is a good T mimic, but also show that it also pairs reasonably well

with G and A. However, a P*-C mismatch is even more destabilizing than a T-T mismatch.

Table 1

5 5'-GTA GAA TTC TTT TCC TTC TAG ATC G-3' 4
 5'-GTA GAA TTC TTT PCC TTC TAG ATC G-3' 5
 3'-CAT CTT AAG AAA AGG AAG ATC TAG C-5' 6
 GG AAG ATC TAG-5' 7

	Base Pair	ΔH°	ΔS°	ΔG°
		(kcal/mol)	(kcal/mol·K)	(kcal/mol)
10	T-A	-195.9	-0.5548	-30.5
	P*-A	-187.7	-0.5382	-27.2
	P*-T	-163.9	-0.469	-24.1
	P*-G	-154.4	-0.440	-23.2
15	P*-C	-143.1	-0.408	-21.5
	T-T	-145.6	-0.412	-22.7

EXAMPLE 2

20 Use of P* base in Primer Extension

The ability of the P* base to support primer extension reactions was studied. Using 5'-end-labeled primer 7 (see Table 1) and template 5 (see Table 1) with *E. coli* DNA polymerase I or Klenow DNA polymerase
 25 and relatively high concentrations (100 μ M) of single dNTPs, extension products were obtained with G, C, and T (see Fig. 2). Primer 7 (see Table 1) was fully

extended in the presence of all four dNTPs even at ordinary concentrations. The resulting duplex was end-labeled and subjected to irradiation at 350 nm, followed by base treatment (piperidine, 95°C or K₂CO₃).

- 5 Analysis of the resulting oligonucleotide fragments suggested that the product was an 12-mer bearing a 3'-phosphate (see Fig. 3).

The P* base-containing nucleoside was converted to triphosphate 3 (Fig. 1) using salicylchlorophosphite
10 (Ludwig et al, Org. Chem. 54:631 (1989)) and used in primer extension with primer 7 (see Table 1) and template 4 (see Table 1). The production of exclusively a pentadecanucleotide shows that the polymerase can incorporate this unnatural base as the
15 incoming triphosphate opposite Ts.

EXAMPLE 3


Synthesis of Photocleavable Nucleoside Triphosphate

A modified nucleotide of the invention can be expected to have application in high throughput
20 screening and sequencing of larger DNA populations using DNA chip technologies such as APEX (Arrayed Primer EXTension). Characteristics of modified nucleotides suitable for use in such technologies include recognition of the nucleotide by DNA
25 polymerase, specificity and predictable strand cleavage. DNA polymerase recognizes the modified nucleoside triphosphate as a substrate or DNA building

block similar to the naturally occurring nucleoside triphosphates. The polymerase specifically places the modified nucleotide opposite only one, or predominantly one, of the naturally occurring nucleotides.

- 5 Predictable strand cleavage is obtained when the DNA containing the modified nucleotide is irradiated with light.

A modified nucleotide of the present invention, a nitropiperonyl deoxyriboside (P)




mimics thymidine in size and shape. The photocleavable moiety is a methylenedioxy-nitrobenzene group cleaved by light of 350 nm. When the modified nucleotide is incorporated into a DNA strand, Klenow fragment DNA polymerase places natural nucleoside triphosphates opposite the modified nucleotide. Moreover, there is specificity in this placement, with dATP being incorporated opposite the modified nucleotide more than the other nucleotide triphosphates. Two of the other

natural nucleotide triphosphates, dGTP and dTTP, are incorporated much less than dATP. The dCTP is not incorporated at all. Further studies have focused on assessing the cleavage characteristics of the

- 5 P-base-containing DNA and on the specificity with which the DNA polymerase recognizes and reacts with the modified P nucleotide.


The synthesis of the target photocleavable nucleotide triphosphate, dPTP, is described below.

- 10 First, 1' α -chloro-3',5'-di-O-toluoyl-2'-deoxyribose was prepared from deoxy-D-ribose according to Hoffer et al as shown in **Scheme 1**. Deoxy-D-ribose was treated with HCl and methanol to generate the methoxy derivative **2** at the anomeric center. Compound **2** was
15 then treated with toluoyl chloride and pyridine to provide the di-protected Compound **3**. The methoxy group was replaced with a chloride by treatment of **3** with HCl gas.



Scheme 1: Synthesis of 1' α -chloro-3',5'-di-O-toluoyl-2'-deoxyribose

The triphosphate **P** was synthesized by the route shown in **Scheme 2**. The Grignard reagent of 4-bromo-1,2-methylenedioxybenzene was generated by treatment with Mg^0 and $CdCl_2$ in THF. This Grignard reagent was allowed to react with Compound **4** to provide the coupled product as a mixture of anomers. The mixture of products was allowed to epimerize by refluxing in toluene for 2 hours, providing predominantly the β -anomer. The anomers were separated by column chromatography and the β -anomer was carried on throughout the remainder of the synthesis. Compound **5** was treated with copper nitrate and acetic anhydride to generate the nitrobenzene derivative **6**. The toluoyl groups were then removed by treatment with sodium methoxide in methanol. The triphosphate group was added to the 5' position of the ribose ring by sequential treatment of **7** with 2-chloro-4H-1,2,3-benzodioxaphosphin-4-one, bis(tri-n-butyl ammonium) pyrophosphate and iodine. The resulting triphosphate **P** was purified by anion exchange chromatography and HPLC.




The optimum DNA polymerase conditions that allow for primer extension using the photocleavable nucleotide (dPTP) and Klenow fragment can be established by one skilled in the art. The first step of the reaction sequence is labelling of the primer PMR-PTP with ^{32}P - γ -ATP as shown below. Initially the product was purified using a Qiagen spin column to separate the primer product from unincorporated ATP and the eluent from the column used without further analysis. Autoradiography after the next primer extension step, however, showed that unincorporated ATP remained in the column eluent. Therefore, the purification of the labelled PRM-PTP primer was changed to a gel purification in which the products are separated by size on a 19% polyacrylamide gel, the desired product excised from the gel, eluted into TE buffer (10 mM Tris, 1 mM EDTA, pH 7.5) and precipitated with ethanol. After resuspension in buffer, the product is then suitable for further use.

20

5' CTA GTA GAA TTC TTT 3'

PRM-PTP



25

5' ^{32}P -CTA GTA GAA TTC TTT 3' ^{32}P -PRM-PTP

Labelling of primer PMR-PTP with ^{32}P - γ -ATP

The next step of the reaction sequence is polymerase extension of the primer with triphosphate dPTP as shown below. Optimization of the polymerase conditions allow the assessment of dPTP as a substrate for DNA polymerases including, but not limited to Klenow fragment. The "standard" conditions (33 μ M dNTP, 0.1 pmol DNA template, 0.1 fmol primer, 5 mM $MgCl_2$, 37 $^{\circ}C$, 15 min) had not provided optimum results. Unmodified dNTPs were used in the optimization experiments instead of the photocleavable dPTP to demonstrate that the conditions are suitable for extension and to conserve dPTP. The concentrations of $MgCl_2$, dNTP (dPTP or the normal dNTP), and changing the reaction time were optimized. The concentrations of $MgCl_2$ was varied between 5 mM, 7.5 mM and 10 mM. The concentrations of dNTP were 0.125 mM, 0.25 mM and 0.5 mM. Increasing both the dNTP concentration and time from 15 min to 30 min allowed for maximum recognition of the modified dPTP by the polymerase. The products were analyzed by autoradiography, however no extension was observed in the experimental samples containing the dPTP. Even though there were some technical difficulties with the electrophoresis equipment, the resolution of the gel was fine, as a difference in mobility between the positive and negative controls, COM-25A + ^{32}P -PRM-PTP + dTTP and unextended PRM-PTP (COM-25A + ^{32}P -PRM-PTP) respectively could be seen. These experiments need to be repeated with a freshly purified portion of dPTP to ensure that degradation of

dPTP was not the source of the problems with the extension reaction.

5' CG ATC TAG AGG XAA AGA ATT CTA C 3' COM-25X
 3' TT TCT TTA AGA TGA TC-³²P 5' ³²P-PRM-PTP

↓ Klenow fragment, dNTP

5' CG ATC TAG AGG XAA AGA ATT CTA C 3'
 3' YTT TCT TTA AGA TGA TC-³²P 5'

10 X= A, C, G, or T
 Y= T, G, C, or A

Extension Reaction

15 * * *


All documents cited above are hereby incorporated in their entirety by reference.

One skilled in the art will appreciate from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention.

20

WHAT IS CLAIMED IS:

1. A compound of formula I




wherein R₁ and R₂ are, independently, -H, -OH or -OY, wherein Y is alkyl,

R₃ and R₄ are, independently, -H, a protecting group, or a mono-, di- or triphosphate, and

X is O or S.

2. The compound according to claim 1 wherein Y is C₁-C₄alkyl.

3. A compound comprising the moiety of formula II




wherein R_1 and R_2 are, independently, -OH, -OH or -OY wherein Y is alkyl, and
X is O or S.


4. The compound according to claim 1 wherein said compound is an oligonucleotide.

5. A method of rendering an oligonucleotide susceptible to site specific cleavage comprising introducing into said oligonucleotide a moiety of formula II.

1/3

**Fig. 1**

2/3

**Fig. 2**

3/3

<i>hν</i>	-	+	+
Piperidine	-	-	+

 ← 25 ← 12-P

Lane 1 2 3

Fig. 3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/15997

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07H 1/02, 21/00, 21/04

US CL :536/24.3, 24.5, 25.3, 25.34, AND 29.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/24.3, 24.5, 25.3, 25.34, AND 29.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

REGISTRY, CAPLUS: NITROPIPERONYL DEOXYRIBOSIDE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Chemical Abstracts, Volume 95, Abstract No. 95:111711p, LIU et al. 28 September 1981, 'The structure of chicanine, a new lignan from Schisandra sp.' Can. J. Chem. 59(11): 1680-1684, 1981.	1-5
A	Chemical Abstracts, Volume 97, Abstract No. 97:107029w, HUANG et al. 27 September 1982, 'Structure of En Shi Zi Su, a new lignan from Schisandra henryi Clarke'. Zhongcaoyao, 1982, 13(2) 22 (Chinese) 1982.	1-5
A	Chemical Abstracts, Volume 90, Abstract No. 90:6216e, KURIHARA et al. 01 January 1979. 'Synthesis and biological activity of 3-quinoline acetic acid derivative'. Yakugaku Zasshi, 1978, 98(6), 802-816, (Japan).	1-5

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 27 SEPTEMBER 1999	Date of mailing of the international search report 20 OCT 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer JOYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX GARY L. KUNZ Telephone No. (703) 308-1236